May 30, 2017 12:31 pm UTC| Business
– NIH investigators to present interim data from the collaborative Phase 2a clinical study of MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis – – Chief Scientific Officer, Dr. Raphael J....
May 30, 2017 12:31 pm UTC| Business
– NIH investigators to present interim data from the collaborative Phase 2a clinical study of MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis – – Chief Scientific Officer, Dr. Raphael J....
May 30, 2017 12:31 pm UTC| Business
– NIH investigators to present interim data from the collaborative Phase 2a clinical study of MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis – – Chief Scientific Officer, Dr. Raphael J....
May 30, 2017 12:31 pm UTC| Business
– NIH investigators to present interim data from the collaborative Phase 2a clinical study of MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis – – Chief Scientific Officer, Dr. Raphael J....
May 30, 2017 12:31 pm UTC| Business
– NIH investigators to present interim data from the collaborative Phase 2a clinical study of MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis – – Chief Scientific Officer, Dr. Raphael J....
May 30, 2017 12:31 pm UTC| Business
– NIH investigators to present interim data from the collaborative Phase 2a clinical study of MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis – – Chief Scientific Officer, Dr. Raphael J....
May 30, 2017 12:31 pm UTC| Business
– NIH investigators to present interim data from the collaborative Phase 2a clinical study of MAT2203 for the treatment of chronic refractory mucocutaneous candidiasis – – Chief Scientific Officer, Dr. Raphael J....